BackAnaptysBio Overview
AnaptysBio Inc

AnaptysBio Target Price

See AnaptysBio's analyst price targets ($77) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$59.69

Average Target Price

$77.2029.3% upside

5 analysts in the last 4 months

High: $90 | Low: $60

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-15Leerink Partners$9050.8% upsideOpen
2026-05-13UBS$7627.3% upsideOpen
2026-05-13Barclays$7525.6% upsideOpen
2026-04-28Leerink Partners$8542.4% upsideOpen
2026-04-21UBS$600.5% upsideOpen
2026-03-06Truist FinancialJohn Lee$5016.2% downsideOpen
2026-03-05Stifel NicolausAlex Thompson$8542.4% upsideOpen
2026-03-04H.C. WainwrightEmily Bodnar$6610.6% upsideOpen
2026-01-07UBSMichael Yee$7017.3% upsideOpen
2025-12-18Guggenheim$140134.5% upsideOpen
2025-12-17BarclaysEtzer Darout$557.9% downsideOpen
2025-12-11Stifel Nicolaus$566.2% downsideOpen
2025-11-11Barclays$7017.3% upsideOpen
2025-11-10WedbushDavid Nierengarten$5016.2% downsideOpen
2025-11-10Truist FinancialJoon Lee$3639.7% downsideOpen
2025-10-29Stifel Nicolaus$8034% upsideOpen
2025-10-15WedbushDavid Nierengarten$7017.3% upsideOpen
2025-10-13Barclays$7830.7% upsideOpen
2025-09-30H.C. Wainwright$591.2% downsideOpen
2025-05-06GuggenheimYatin Suneja$549.5% downsideOpen
2025-03-03Guggenheim$5212.9% downsideOpen
2025-02-04Wolfe ResearchAndy Chen$2558.1% downsideOpen
2024-12-11H.C. WainwrightEmily Bodnar$1968.2% downsideOpen
2024-11-06H.C. WainwrightEmily Bodnar$5212.9% downsideOpen
2024-11-06Leerink PartnersDavid Risinger$4524.6% downsideOpen
2024-10-21GuggenheimYatin Suneja$9050.8% upsideOpen
2024-10-15Piper SandlerYasmeen Rahimi$8034% upsideOpen
2024-10-03New StreetDavid Risinger$3541.4% downsideOpen
2024-08-15Truist FinancialJoon Lee$3049.7% downsideOpen
2024-04-16Leerink PartnersDavid Risinger$4721.3% downsideOpen
2022-11-18J.P. Morgan$3246.4% downsideOpen

AnaptysBio (ANAB) FAQ

The latest target price for ANAB is $77. Investors often review this figure alongside AnaptysBio's historical trend and sector peers before judging valuation or financial health.

AnaptysBio trades near $59.69 while the consensus target sits at $77 (29.3% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ANAB's target price ($77), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AnaptysBio's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.